There is no cure for osteogenesis imperfecta (OI). Current treatments focus on strengthening bones, reducing fractures, and improving mobility, but none can fix the underlying genetic defect that causes the condition. OI affects roughly 1 in every 16,000 to 20,000 births and ranges from mild cases with occasional fractures to severe forms that can be life-threatening in infancy.
That said, the treatment landscape is broader and more promising than it was even a decade ago. Gene editing, stem cell transplants, and newer bone-building medications are all in active development, and some have shown striking early results.
What Causes OI and Why It’s Hard to Cure
OI is caused by mutations in genes responsible for producing type I collagen, the protein that gives bones their flexibility and strength. In milder forms (Type I), the body simply makes too little collagen, but the collagen it does produce is structurally normal. In more severe forms (Types II, III, and IV), the mutations produce abnormal collagen molecules that weaken the entire skeletal framework. Type II, the most severe, can cause underdeveloped lungs and an extremely fragile rib cage, and infants with this form often do not survive.
Because the defect is written into nearly every cell that builds bone, a true cure would require either replacing or correcting the faulty gene across a large population of cells. That’s a fundamentally different challenge from treating a condition caused by a single organ or a circulating protein. The collagen-producing cells are spread throughout the skeleton, making them difficult to reach with any single therapy.
How OI Types Differ in Severity
OI is classified into several types. Understanding which type someone has shapes everything about their treatment and outlook.
- Type I is the mildest form. People typically reach normal or near-normal height, experience fractures mainly during childhood from minor falls, and see fracture rates drop in adulthood. About half develop hearing loss later in life, and many have a blue or grey tint to the whites of their eyes.
- Type II is the most severe and is often fatal at or shortly after birth due to an extremely fragile skeleton and underdeveloped lungs.
- Types III and IV fall between these extremes, with progressive bone deformity, short stature, spinal curvature, and varying degrees of reduced mobility. Some people with these types use walkers or wheelchairs.
- Type V is a distinct genetic variant with its own inheritance pattern and features like dense bone bands visible on X-rays.
Most cases of Types I and IV are inherited from a parent. The more severe forms (Types II and III) usually arise from new, spontaneous mutations with no family history.
Medications That Slow Bone Loss
The most widely used medications for OI are bisphosphonates, drugs that slow the breakdown of bone. They don’t build new healthy bone or correct the collagen defect, but they help preserve existing bone mass and can reduce fracture rates, especially in children. Some are taken as pills, while others are given through IV infusions every few months. In children with moderate to severe OI, IV bisphosphonates are often started early in life and continued through the growing years.
A newer option being explored is a class of drugs that blocks a protein called sclerostin, which normally puts the brakes on bone formation. In one reported case, a patient with severe OI (Type III) treated with the sclerostin inhibitor romosozumab saw bone density increase by over 20% at the spine and 35% at the hip over a year, with no fragility fractures during that period. A previous case in a man with Type I OI showed similarly dramatic improvements. A clinical trial of another sclerostin inhibitor, setrusumab, has been completed in patients with Types I, III, and IV, with results pending. These drugs work differently from bisphosphonates because they actively stimulate new bone formation rather than just slowing bone loss.
Denosumab, a medication that blocks a different bone-resorption pathway, has also been studied in children with OI. A prospective comparative study found it lowered certain bone formation markers but, surprisingly, did not reduce bone resorption levels the way bisphosphonates did. Researchers also flagged a risk of rebound high calcium levels when the drug wears off, particularly in children with high bone turnover. Its role in OI treatment is still being defined.
Surgery to Stabilize Bones
For children with repeated fractures or bones that bow and deform as they grow, surgeons can place metal rods inside the long bones of the legs and arms. The most commonly used device worldwide is the Fassier-Duval rod, a telescoping rod designed to lengthen as a child grows, avoiding the need for frequent replacement surgeries.
Fracture is the primary reason these rods are implanted, accounting for about 67% of cases in one large study. Telescoping rods generally perform well, with roughly 79% still functioning at three years. The main reasons rods eventually need replacing are new fractures around the rod, the rod migrating out of position, or, rarely, infection. Revision rates over five years range from about 36% to 46% depending on the rod type, so families should expect that additional surgeries may be needed as a child grows.
Physical Therapy and Daily Life
Physical rehabilitation is a core part of OI management, not an optional add-on. The goal is to build as much muscle strength and functional ability as safely possible, since stronger muscles help protect fragile bones.
For children, therapy typically follows a developmental sequence: first building head and trunk control, then seated balance, then progressing toward standing and walking. Strengthening exercises start in supported positions (lying down, then sitting) before advancing to more challenging ones. Range-of-motion exercises begin passively, with a therapist moving the joints, then progress to the child doing them independently. Balance training, gait training with appropriate support devices, and functional activities like reaching and climbing stairs are layered in over time. Early encouragement to move actively within a safe environment, even after fractures, leads to better outcomes than prolonged immobilization.
Gene Therapy and Stem Cell Research
The closest thing to a potential cure lies in gene therapy and stem cell transplantation, though neither is available as a standard treatment yet.
CRISPR gene editing has shown proof-of-concept results in lab settings. Researchers have used it to disrupt the mutant copy of the collagen gene in cells taken from OI patients, and they’ve successfully repaired mutations in stem cells derived from patient blood cells. The challenge is efficiency: the editing tools need to correct enough cells to make a meaningful difference in the whole skeleton. Base editing, a newer refinement of CRISPR, can make precise single-letter changes in DNA and has already been used to treat blood disorders in mice, but it hasn’t yet been applied to bone-forming cells. Current limitations include the fact that some editing methods only work on dividing cells, and the range of mutations each technique can address is narrow.
Stem cell transplants have been tested in a small number of patients. Mesenchymal stem cells, which can develop into bone-forming cells, have been isolated from donors and infused into people with OI. The results so far show that these cells are safe, they do migrate to fracture sites and growth areas in bone, and they can improve clinical outcomes. But the benefits tend to be temporary, likely because the transplanted cells work mainly through signaling to the body’s own cells rather than permanently replacing defective ones. Engraftment levels remain low, meaning only a small fraction of the donated cells take up permanent residence in the patient’s bones. The TERCELOI clinical trial evaluated repeated injections of donor stem cells in OI patients and reported some benefit, but the approach is still experimental.
Combining gene editing with stem cell therapy represents a logical next step: correcting a patient’s own stem cells in the lab and then transplanting them back. This would sidestep immune rejection and potentially provide a lasting source of normal collagen-producing cells. That combination remains in preclinical stages.
What Treatment Looks Like Today
Managing OI requires a team: orthopedic surgeons, endocrinologists, physical therapists, and occupational therapists working together. For a child with moderate OI, a typical path might include IV bisphosphonate infusions starting in infancy, physical therapy several times a week, rodding surgery on the femurs or tibias if fractures recur or bones bow significantly, and ongoing monitoring of bone density, hearing, and spinal alignment.
Adults with milder forms often find that fracture rates decrease significantly after puberty. Their focus tends to shift toward maintaining bone density, staying physically active to preserve muscle strength, and monitoring for hearing loss. For those with more severe types, mobility aids, adapted living environments, and continued physical therapy remain part of daily life. The condition is lifelong, and while the available treatments can meaningfully reduce its impact, they require sustained commitment over years and decades.